Bridgefront Capital LLC purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,555 shares of the company's stock, valued at approximately $893,000.
A number of other hedge funds have also modified their holdings of AXSM. Barclays PLC lifted its position in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock worth $5,552,000 after buying an additional 45,509 shares in the last quarter. Franklin Resources Inc. boosted its position in Axsome Therapeutics by 47.5% during the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock valued at $13,713,000 after purchasing an additional 51,696 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after purchasing an additional 27,534 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $2,237,000. Finally, Flower City Capital bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $254,000. 81.49% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.30% of the stock is owned by company insiders.
Axsome Therapeutics Stock Performance
Shares of NASDAQ:AXSM traded down $1.10 on Friday, reaching $107.76. 435,267 shares of the company's stock were exchanged, compared to its average volume of 682,018. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a fifty day moving average of $112.01 and a 200-day moving average of $104.51. The company has a market capitalization of $5.31 billion, a price-to-earnings ratio of -17.99 and a beta of 0.46. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on AXSM shares. Morgan Stanley boosted their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Wells Fargo & Company reiterated an "overweight" rating and set a $165.00 target price (up from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday. Finally, William Blair restated an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $172.14.
Get Our Latest Report on AXSM
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading

Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.